Industry analytics
Pharmaceutical Preparations
SIC 2834. A view of the 20 companies in this industry that Stratum has processed into structured data.
- Population
- 20 companiesSIC 2834 · 16 report USD revenue
- Period
- Latest year per companytrends by fiscal year, medians of whoever reported
- Geography
- 6 jurisdictionsof incorporation
- Minimum group
- 3 companiessmaller groups show no statistic
- Combined revenue
- $56.11Bsum of each company's latest annual USD revenue
- Median revenue growth
- 10.4%14 companies
- Median operating margin
- -496.9%15 companies
- Median net margin
- -488.0%16 companies
What is changing
Median by fiscal year across the companies that reported, with the middle half of companies shaded. A year needs 3 companies to be plotted.
- Median revenue growth moved from 15.3% in FY2024 to 0.0% in FY2025 (-15.3 pp).Based on 4 then 5 companies; median of the companies reporting in each year.
- Median operating margin moved from -2.0% in FY2024 to -26.4% in FY2025 (-24.3 pp).Based on 4 then 5 companies; median of the companies reporting in each year.
- Median net margin moved from -9.8% in FY2024 to -19.6% in FY2025 (-9.8 pp).Based on 5 then 6 companies; median of the companies reporting in each year.
Operating margin
| Fiscal year | Companies | 25th percentile | Median | 75th percentile |
|---|---|---|---|---|
| FY2009 | 1 | not reported (fewer than 3 companies) | ||
| FY2010 | 2 | not reported (fewer than 3 companies) | ||
| FY2011 | 2 | not reported (fewer than 3 companies) | ||
| FY2013 | 2 | not reported (fewer than 3 companies) | ||
| FY2014 | 2 | not reported (fewer than 3 companies) | ||
| FY2015 | 3 | -29654.7% | -718.4% | -366.2% |
| FY2016 | 2 | not reported (fewer than 3 companies) | ||
| FY2017 | 1 | not reported (fewer than 3 companies) | ||
| FY2021 | 1 | not reported (fewer than 3 companies) | ||
| FY2022 | 3 | -4277.9% | -993.9% | -506.6% |
| FY2023 | 5 | -33.6% | -3.8% | 3.3% |
| FY2024 | 4 | -742.0% | -2.0% | 13.9% |
| FY2025 | 5 | -1384.6% | -26.4% | -1.1% |
Net margin
| Fiscal year | Companies | 25th percentile | Median | 75th percentile |
|---|---|---|---|---|
| FY2009 | 1 | not reported (fewer than 3 companies) | ||
| FY2010 | 2 | not reported (fewer than 3 companies) | ||
| FY2011 | 2 | not reported (fewer than 3 companies) | ||
| FY2013 | 2 | not reported (fewer than 3 companies) | ||
| FY2014 | 2 | not reported (fewer than 3 companies) | ||
| FY2015 | 3 | -79513.1% | -6.9% | 107.0% |
| FY2016 | 2 | not reported (fewer than 3 companies) | ||
| FY2017 | 1 | not reported (fewer than 3 companies) | ||
| FY2021 | 1 | not reported (fewer than 3 companies) | ||
| FY2022 | 3 | -5676.2% | -880.7% | -500.7% |
| FY2023 | 6 | -68.3% | -1.6% | 13.3% |
| FY2024 | 5 | -18.5% | -9.8% | -3.9% |
| FY2025 | 6 | -996.0% | -19.6% | 9.5% |
Revenue growth
| Fiscal year | Companies | 25th percentile | Median | 75th percentile |
|---|---|---|---|---|
| FY2010 | 1 | not reported (fewer than 3 companies) | ||
| FY2011 | 1 | not reported (fewer than 3 companies) | ||
| FY2014 | 2 | not reported (fewer than 3 companies) | ||
| FY2015 | 1 | not reported (fewer than 3 companies) | ||
| FY2016 | 1 | not reported (fewer than 3 companies) | ||
| FY2017 | 1 | not reported (fewer than 3 companies) | ||
| FY2022 | 1 | not reported (fewer than 3 companies) | ||
| FY2023 | 2 | not reported (fewer than 3 companies) | ||
| FY2024 | 4 | 4.0% | 15.3% | 23.4% |
| FY2025 | 5 | -0.2% | 0.0% | 10.6% |
How companies compare today
Each company's latest year. Bars are counts of companies; the dashed line is the median.
Operating margin · 15 companies
| Range | Companies |
|---|---|
| -4099.0% to -3753.5% | 2 |
| -3753.5% to -3408.0% | 0 |
| -3408.0% to -3062.5% | 0 |
| -3062.5% to -2717.0% | 0 |
| -2717.0% to -2371.5% | 1 |
| -2371.5% to -2026.0% | 0 |
| -2026.0% to -1680.5% | 1 |
| -1680.5% to -1335.1% | 1 |
| -1335.1% to -989.6% | 1 |
| -989.6% to -644.1% | 1 |
| -644.1% to -298.6% | 1 |
| -298.6% to 46.9% | 7 |
25th -1651.7% · median -496.9% · 75th -20.2%
2 of 15 companies lie outside the Tukey fences (-4099.0% to 2427.1%): 2 below, 0 above. They are flagged, not removed; every percentile and the table include them, and the end bins of the histogram count them.
Revenue growth · 14 companies
| Range | Companies |
|---|---|
| -29.2% to -3.6% | 1 |
| -3.6% to 21.9% | 7 |
| 21.9% to 47.5% | 0 |
| 47.5% to 73.0% | 1 |
| 73.0% to 98.6% | 0 |
| 98.6% to 124.1% | 2 |
| 124.1% to 149.7% | 0 |
| 149.7% to 175.2% | 0 |
| 175.2% to 200.8% | 0 |
| 200.8% to 226.3% | 0 |
| 226.3% to 251.9% | 0 |
| 251.9% to 277.4% | 3 |
25th -0.2% · median 10.4% · 75th 110.9%
3 of 14 companies lie outside the Tukey fences (-166.7% to 277.4%): 0 below, 3 above. They are flagged, not removed; every percentile and the table include them, and the end bins of the histogram count them.
Largest companies
By latest annual revenue reported in US dollars.
| Company | Revenue | Operating margin |
|---|---|---|
| BRISTOL MYERS SQUIBB COBMY | $48.19BFY2025 | — |
| PERRIGO Co plcPRGO | $4.25BFY2025 | -26.4% |
| UNITED THERAPEUTICS CorpUTHR | $3.18BFY2025 | 46.9% |
| Sagent Pharmaceuticals, Inc. | $318.3MFY2015 | -14.0% |
| Eton Pharmaceuticals, Inc.ETON | $80.0MFY2025 | -1.1% |
| BODY & MIND INC. | $22.8MFY2023 | -33.6% |
| VIADERMA, INC. | $19.0MFY2011 | 21.2% |
| Centessa Pharmaceuticals plc | $15.0MFY2025 | -1384.6% |
| Provention Bio, Inc. | $12.9MFY2022 | -993.9% |
| VBI Vaccines Inc/BC | $8.7MFY2023 | -920.4% |
Where they are incorporated
Jurisdiction of incorporation from SEC records. It is not where sales or operations are.
Recent reports
The latest filings by companies in this industry in the structured data layer.
AI interpretation
Describes what the statistics above show for Pharmaceutical Preparations. The AI words statistics that were computed in code; it cannot add, change or estimate any figure, and each statement is checked before it is shown.